Detalles de la búsqueda
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994647
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
3.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517286
4.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38685853
5.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983642
6.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
J Med Virol
; 95(1): e28210, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222204
7.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs
; 41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
8.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
9.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
10.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
11.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36657420
12.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Hepatol Res
; 53(2): 172-178, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36214071
13.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020416
14.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
15.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
16.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat
; 29(7): 551-558, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35548866
17.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Invest New Drugs
; 40(6): 1290-1297, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152108
18.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103846
19.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080087
20.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34799975